BioIntelliSense Inc.

BioIntelliSense develops continuous patient monitoring systems for in-facility and home care settings. The company's flagship product, the BioButton wearable device, captures multiparameter vital signs and biometric data in real time, enabling proactive detection of patient deterioration. The system integrates flexible connectivity options (BioMobile app, BioHub Cellular gateway, BioHub Wi-Fi gateway) with BioDashboard clinical intelligence software for exception-based monitoring and analysis. Clinical studies demonstrate that continuous monitoring reduces unplanned ICU admissions, rapid response team activations, and average length of hospital stay. The platform supports operational efficiency initiatives including length-of-stay reduction, virtual rounding optimization, and telemetry overuse reduction. BioIntelliSense targets hospitals, health systems, skilled nursing facilities, assisted living, home health agencies, and remote patient monitoring providers. The company emphasizes evidence-based outcomes from peer-reviewed publications, including research in the Journal of Clinical Medicine and British Journal of Anaesthesia. Products are designed for both acute care floor monitoring and post-acute care transitions, with reimbursement support for remote patient monitoring (RPM) programs. The system is described as medical-grade and designed for healthcare provider organizations only, not direct consumer purchase.